4//SEC Filing
Jovan-Embiricos Morana 4
Accession 0001104659-22-075392
CIK 0001789972other
Filed
Jun 27, 8:00 PM ET
Accepted
Jun 28, 9:24 PM ET
Size
23.7 KB
Accession
0001104659-22-075392
Insider Transaction Report
Form 4
Jovan-Embiricos Morana
Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2022-06-24$4.30/sh+104,845$450,834→ 217,352 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-06-24−35,529→ 0 totalExercise: $4.30Exp: 2022-06-30→ Common Stock (35,529 underlying) - Tax Payment
Common Stock
2022-06-24$13.39/sh−45,078$603,594→ 207,803 total - Exercise/Conversion
Common Stock
2022-06-24$4.30/sh+35,529$152,775→ 252,881 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-06-24−104,845→ 0 totalExercise: $4.30Exp: 2022-06-30→ Common Stock (104,845 underlying)
Holdings
- 1,136,525(indirect: By Globeways Holdings Ltd.)
Common Stock
- 325,333(indirect: By F2 MG Ltd.)
Common Stock
- 537,392(indirect: By F2 Bioscience I 2017 Ltd.)
Common Stock
- 1,305,873(indirect: By F2 Vision SCS)
Common Stock
- 622,175(indirect: By LLC)
Common Stock
- 214,798(indirect: By LLC)
Common Stock
- 71,599(indirect: By LLC)
Common Stock
- 104,762(indirect: By LLC)
Common Stock
Footnotes (10)
- [F1]Represents a net exercise of outstanding stock options. These shares were resold to the Issuer as payment of the exercise price, based on the closing price of the Issuer's common stock on June 24, 2022 of $13.39 per share.
- [F10]The shares subject to this option are fully vested and exercisable as of the date hereof.
- [F2]These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F3]These securities are owned directly by Globeways. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F4]These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Dr. Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F5]These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F6]These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F7]These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F8]These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F9]These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Cullinan Oncology, Inc.
CIK 0001789972
Entity typeother
Related Parties
1- filerCIK 0001575745
Filing Metadata
- Form type
- 4
- Filed
- Jun 27, 8:00 PM ET
- Accepted
- Jun 28, 9:24 PM ET
- Size
- 23.7 KB